8th T-Cell Engager Therapeutics Summit

The T-cell engager field is advancing faster than ever. With multiple clinical approvals validating the staying power of this modality, and a new wave of next-generation solid tumor and autoimmune programs moving rapidly towards the clinic, the momentum behind T-Cell engagers has never been stronger. These therapies are increasingly cited as one of the most promising drivers of the next era of immunotherapy.

Over the past year, the sector has experienced a surge of investment, deal-making and strategic collaboration. Landmark partnerships such as BMS x JanuX Therapeutics, Candid Therapeutics x WuXi Biologics and AbbVie x EvolveImmune signal growing confidence in the transformative potential of immune-redirecting platforms and reinforce commitment to advancing TCE innovation across oncology and autoimmune disease.

Moving from Boston to San Diego for 2026, the 8th T-Cell Engager Therapeutics Summit stands as the industry’s most comprehensive end-to-end meeting dedicated to advancing, optimizing and translating T-cell engagers.

This case-study driven forum is designed to equip engineering, discovery, R and D, translational and clinical development teams with the actionable insights needed to engineer safer, more potent, durable and precisely targets TCEs for solid tumors, while also spotlighting the breakthroughs extending engager biology into autoimmune and inflammatory diseases.

If accelerating your TCE pipeline is a priority, this is a meeting you cannot afford to miss.

URLs:
Website: https://go.evvnt.com/3501952-0?pid=5413
Tickets: https://go.evvnt.com/3501952-2?pid=5413
Brochure: https://go.evvnt.com/3501952-3?pid=5413

Prices:
Conference + Workshop Day – Drug Developer Pricing: USD 4397.00,
Conference Only – Drug Developer Pricing: USD 3099.00,
Conference + Workshop Day – Academic Pricing: USD 3797.00,
Conference Only – Academic Pricing: USD 2699.00,
Conference + Workshop Day – Service Provider Pricing: USD 5297.00,
Conference Only – Service Provider Pricing: USD 3799.00

Speakers: Ran You Principal Scienitst Amgen, Saso Cemerski Executive Director, Head of Immune Engagers AstraZeneca, Jonah Rainey Associate Vice President Eli Lilly and Co., Nicole Schirle Oakdale Principal Scientist Gilead Sciences, Mehabaw Derebe Principal Scientist Merck and Co, Alison Crawford Director – Immuno Oncology Regeneron Pharmaceuticals, Vesna Kramar Senior Scientist Roche, Barbara Sennino Senior Vice President and Head of Early Development 3T Biosciences, Alex Martinko Senior Director – Antibody Engineering and Design Cartography Biosciences, Inc, Mike Maloney Director – Immunology Clasp Therapeutics, Jack Silberstein CEO and Founder Deck Bio, Martin Preyer Executive Director – Biotherapeutics EvolveImmune Therapeutics, Michael Dyson Vice President – Antibody Discovery and Engineering Ichnos Glenmark Innovation, Lawrence Lamb Executive Vice President and Chief Scientific Officer IN8Bio, Suzette Girgis Vice President and Head of Global Clinical Pharmacology and Pharmacometrics Jazz Pharmaceuticals, Daniel Foxler Cell Biology and Assay Development Head LabGenius, Xavier Parot Senior Medical Director ModeX Therapeutics, Lauren Pitt Preclinical Development Head MyrioTx, Surge Biswas Co-Founder and Chief Executive Officer Nabla Bio, Shihao chen Co-Founder QLSF Biotherapeutics, Udaya Rangaswamy Senior Director – Translational Biology Rondo Therapeutics, Rachel Rennard Senior Vice President – Research Stereo Biotherapeutics, Nathaniel Davies Senior Director Computational Biology T-Cypher Bio, Martin Pflügler Chief Executive Officer and Founder Twyce Therapeutics, Jennifer Towne Chief Scientific Officer and Executive Vice President Vir Biotechnology, Kendra Avery Director Xencor, Genevieve Desjardins Principal Scientist – Protein Engineering Zymeworks

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Date and Time: 23rd June 2026 at 7:30 am to 25th June 2026 at 5:30 pm

Venue details: The Westin San Diego Bayview, 1051 Columbia Street, San Diego, California, 92101, United States